PDCD1 and hepatocellular carcinoma: Subgroup analysis of IMbrave150 highlighted the efficacy and safety of treatment with atezolizumab plus bevacizumab in the Chinese HCC population (19), and more trials of PD-1/L1 inhibitors combined with anti-angiogenic drugs for HCC in China are underway, but the sample size of which is small (20–22).